Cargando…
Assessment of Reye’s syndrome profile with data from the US Food and Drug Administration Adverse Event Reporting System and the Japanese Adverse Drug Event Report databases using the disproportionality analysis
OBJECTIVES: Reye’s syndrome is a rare and potentially fatal illness that is defined as encephalopathy accompanied by liver failure. The aim of this study was to assess Reye’s syndrome profiles by analyzing data from the spontaneous reporting system database. METHODS: We analyzed reports of Reye’s sy...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7686594/ https://www.ncbi.nlm.nih.gov/pubmed/33282307 http://dx.doi.org/10.1177/2050312120974176 |
_version_ | 1783613359438954496 |
---|---|
author | Matsumoto, Kiyoka Hasegawa, Shiori Nakao, Satoshi Shimada, Kazuyo Mukai, Ririka Tanaka, Mizuki Satake, Riko Yoshida, Yu Goto, Fumiya Inoue, Misaki Ikesue, Hiroaki Iguchi, Kazuhiro Hashida, Tohru Nakamura, Mitsuhiro |
author_facet | Matsumoto, Kiyoka Hasegawa, Shiori Nakao, Satoshi Shimada, Kazuyo Mukai, Ririka Tanaka, Mizuki Satake, Riko Yoshida, Yu Goto, Fumiya Inoue, Misaki Ikesue, Hiroaki Iguchi, Kazuhiro Hashida, Tohru Nakamura, Mitsuhiro |
author_sort | Matsumoto, Kiyoka |
collection | PubMed |
description | OBJECTIVES: Reye’s syndrome is a rare and potentially fatal illness that is defined as encephalopathy accompanied by liver failure. The aim of this study was to assess Reye’s syndrome profiles by analyzing data from the spontaneous reporting system database. METHODS: We analyzed reports of Reye’s syndrome using the US Food and Drug Administration Adverse Event Reporting System and the Japanese Adverse Drug Event Report databases. The reporting odds ratio and proportional reporting rate were used to detect the pharmacovigilance signal. RESULTS: The US Food and Drug Administration Adverse Event Reporting System contains 12,201,620 reports from January 2004 to June 2020, of which 186 are on Reye’s syndrome. The Japanese Adverse Drug Event Report contains 646,779 reports from April 2004 to September 2020, of which 30 are on Reye’s syndrome. In the US Food and Drug Administration Adverse Event Reporting System database, the reporting odds ratios (95% confidence interval, number of cases) of aspirin, diclofenac, ibuprofen, acetaminophen, and valproate sodium were 404.6 (302.6–541.0, n = 80), 15.1 (6.7–34.1, n = 6), 26.2 (16.1–42.6, n = 18), 10.7 (5.5–20.9, n = 9), and 47.1 (26.2–84.6, n = 12), respectively. In the Japanese Adverse Drug Event Report database, the reporting odds ratios (95% confidence interval, number of cases) of aspirin, diclofenac, ibuprofen, loxoprofen, acetaminophen, and valproate sodium were 14.1 (5.4–36.8, n = 5), 51.7 (22.2–120.5, n = 7), 135.0 (40.8–446.2, n = 3), 17.6 (6.7–46.0, n = 5), 24.0 (9.2–62.6, n = 5), and 13.8 (3.3–57.9, n = 2), respectively. The reported number of female patients aged 30–39 years was the highest in the Japanese Adverse Drug Event Report. CONCLUSION: Although the frequency of the occurrence of Reye’s syndrome is low, the possible risk of the disease occurring in adult females should be considered. |
format | Online Article Text |
id | pubmed-7686594 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-76865942020-12-03 Assessment of Reye’s syndrome profile with data from the US Food and Drug Administration Adverse Event Reporting System and the Japanese Adverse Drug Event Report databases using the disproportionality analysis Matsumoto, Kiyoka Hasegawa, Shiori Nakao, Satoshi Shimada, Kazuyo Mukai, Ririka Tanaka, Mizuki Satake, Riko Yoshida, Yu Goto, Fumiya Inoue, Misaki Ikesue, Hiroaki Iguchi, Kazuhiro Hashida, Tohru Nakamura, Mitsuhiro SAGE Open Med Original Article OBJECTIVES: Reye’s syndrome is a rare and potentially fatal illness that is defined as encephalopathy accompanied by liver failure. The aim of this study was to assess Reye’s syndrome profiles by analyzing data from the spontaneous reporting system database. METHODS: We analyzed reports of Reye’s syndrome using the US Food and Drug Administration Adverse Event Reporting System and the Japanese Adverse Drug Event Report databases. The reporting odds ratio and proportional reporting rate were used to detect the pharmacovigilance signal. RESULTS: The US Food and Drug Administration Adverse Event Reporting System contains 12,201,620 reports from January 2004 to June 2020, of which 186 are on Reye’s syndrome. The Japanese Adverse Drug Event Report contains 646,779 reports from April 2004 to September 2020, of which 30 are on Reye’s syndrome. In the US Food and Drug Administration Adverse Event Reporting System database, the reporting odds ratios (95% confidence interval, number of cases) of aspirin, diclofenac, ibuprofen, acetaminophen, and valproate sodium were 404.6 (302.6–541.0, n = 80), 15.1 (6.7–34.1, n = 6), 26.2 (16.1–42.6, n = 18), 10.7 (5.5–20.9, n = 9), and 47.1 (26.2–84.6, n = 12), respectively. In the Japanese Adverse Drug Event Report database, the reporting odds ratios (95% confidence interval, number of cases) of aspirin, diclofenac, ibuprofen, loxoprofen, acetaminophen, and valproate sodium were 14.1 (5.4–36.8, n = 5), 51.7 (22.2–120.5, n = 7), 135.0 (40.8–446.2, n = 3), 17.6 (6.7–46.0, n = 5), 24.0 (9.2–62.6, n = 5), and 13.8 (3.3–57.9, n = 2), respectively. The reported number of female patients aged 30–39 years was the highest in the Japanese Adverse Drug Event Report. CONCLUSION: Although the frequency of the occurrence of Reye’s syndrome is low, the possible risk of the disease occurring in adult females should be considered. SAGE Publications 2020-11-20 /pmc/articles/PMC7686594/ /pubmed/33282307 http://dx.doi.org/10.1177/2050312120974176 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Original Article Matsumoto, Kiyoka Hasegawa, Shiori Nakao, Satoshi Shimada, Kazuyo Mukai, Ririka Tanaka, Mizuki Satake, Riko Yoshida, Yu Goto, Fumiya Inoue, Misaki Ikesue, Hiroaki Iguchi, Kazuhiro Hashida, Tohru Nakamura, Mitsuhiro Assessment of Reye’s syndrome profile with data from the US Food and Drug Administration Adverse Event Reporting System and the Japanese Adverse Drug Event Report databases using the disproportionality analysis |
title | Assessment of Reye’s syndrome profile with data from the US Food and
Drug Administration Adverse Event Reporting System and the Japanese Adverse Drug
Event Report databases using the disproportionality analysis |
title_full | Assessment of Reye’s syndrome profile with data from the US Food and
Drug Administration Adverse Event Reporting System and the Japanese Adverse Drug
Event Report databases using the disproportionality analysis |
title_fullStr | Assessment of Reye’s syndrome profile with data from the US Food and
Drug Administration Adverse Event Reporting System and the Japanese Adverse Drug
Event Report databases using the disproportionality analysis |
title_full_unstemmed | Assessment of Reye’s syndrome profile with data from the US Food and
Drug Administration Adverse Event Reporting System and the Japanese Adverse Drug
Event Report databases using the disproportionality analysis |
title_short | Assessment of Reye’s syndrome profile with data from the US Food and
Drug Administration Adverse Event Reporting System and the Japanese Adverse Drug
Event Report databases using the disproportionality analysis |
title_sort | assessment of reye’s syndrome profile with data from the us food and
drug administration adverse event reporting system and the japanese adverse drug
event report databases using the disproportionality analysis |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7686594/ https://www.ncbi.nlm.nih.gov/pubmed/33282307 http://dx.doi.org/10.1177/2050312120974176 |
work_keys_str_mv | AT matsumotokiyoka assessmentofreyessyndromeprofilewithdatafromtheusfoodanddrugadministrationadverseeventreportingsystemandthejapaneseadversedrugeventreportdatabasesusingthedisproportionalityanalysis AT hasegawashiori assessmentofreyessyndromeprofilewithdatafromtheusfoodanddrugadministrationadverseeventreportingsystemandthejapaneseadversedrugeventreportdatabasesusingthedisproportionalityanalysis AT nakaosatoshi assessmentofreyessyndromeprofilewithdatafromtheusfoodanddrugadministrationadverseeventreportingsystemandthejapaneseadversedrugeventreportdatabasesusingthedisproportionalityanalysis AT shimadakazuyo assessmentofreyessyndromeprofilewithdatafromtheusfoodanddrugadministrationadverseeventreportingsystemandthejapaneseadversedrugeventreportdatabasesusingthedisproportionalityanalysis AT mukairirika assessmentofreyessyndromeprofilewithdatafromtheusfoodanddrugadministrationadverseeventreportingsystemandthejapaneseadversedrugeventreportdatabasesusingthedisproportionalityanalysis AT tanakamizuki assessmentofreyessyndromeprofilewithdatafromtheusfoodanddrugadministrationadverseeventreportingsystemandthejapaneseadversedrugeventreportdatabasesusingthedisproportionalityanalysis AT satakeriko assessmentofreyessyndromeprofilewithdatafromtheusfoodanddrugadministrationadverseeventreportingsystemandthejapaneseadversedrugeventreportdatabasesusingthedisproportionalityanalysis AT yoshidayu assessmentofreyessyndromeprofilewithdatafromtheusfoodanddrugadministrationadverseeventreportingsystemandthejapaneseadversedrugeventreportdatabasesusingthedisproportionalityanalysis AT gotofumiya assessmentofreyessyndromeprofilewithdatafromtheusfoodanddrugadministrationadverseeventreportingsystemandthejapaneseadversedrugeventreportdatabasesusingthedisproportionalityanalysis AT inouemisaki assessmentofreyessyndromeprofilewithdatafromtheusfoodanddrugadministrationadverseeventreportingsystemandthejapaneseadversedrugeventreportdatabasesusingthedisproportionalityanalysis AT ikesuehiroaki assessmentofreyessyndromeprofilewithdatafromtheusfoodanddrugadministrationadverseeventreportingsystemandthejapaneseadversedrugeventreportdatabasesusingthedisproportionalityanalysis AT iguchikazuhiro assessmentofreyessyndromeprofilewithdatafromtheusfoodanddrugadministrationadverseeventreportingsystemandthejapaneseadversedrugeventreportdatabasesusingthedisproportionalityanalysis AT hashidatohru assessmentofreyessyndromeprofilewithdatafromtheusfoodanddrugadministrationadverseeventreportingsystemandthejapaneseadversedrugeventreportdatabasesusingthedisproportionalityanalysis AT nakamuramitsuhiro assessmentofreyessyndromeprofilewithdatafromtheusfoodanddrugadministrationadverseeventreportingsystemandthejapaneseadversedrugeventreportdatabasesusingthedisproportionalityanalysis |